Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
Black Diamond Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying
黑钻疗法和其他两只低于3美元的股票内部人士正在买入
Don't forget to check out our premarket coverage here The Dow Jones closed lower by around 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周四收盘下跌约250点。当内部人士购买或出售股票时，这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将其视为其整体投资或交易决策中的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多，请查看 本辛加的内幕交易 平台。
Black Diamond Therapeutics
黑钻疗法
- The Trade: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) 10% owner BB Biotech AG acquired a total of 400,000 shares an average price of $2.34. To acquire these shares, it cost around $934,080.
- What's Happening: Black Diamond Therapeutics presented dose escalation data demonstrating durable responses in patients with NSCLC from Phase 1 trial of BDTX-1535 at the AACR-NCI-EORTC International Conference.
- What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies.
- 交易： 黑钻治疗公司 (纳斯达克股票代码：BDTX) 10% 的所有者 BB Biotech AG 共收购40万股股票 平均价格为2.34美元。收购这些股票的成本约为934,080美元。
- 发生了什么： Black Diamond Therapeutics在AACR-NCI-EORTC国际会议上公布了剂量递增数据，显示了来自 BDTX-1535 一期试验的非小细胞肺癌患者的持久反应。
- 黑钻疗法的作用： 黑钻治疗公司是一家精准肿瘤医学公司。它从事小分子、与肿瘤无关的疗法的发现和开发。
Bespoke Extracts
定制摘录
- The Trade: Bespoke Extracts, Inc. (OTC:BSPK) CEO Michael Feinsod acquired a total of 3,000 shares at an average price of $0.20. To acquire these shares, it cost around $560.
- What's Happening: The company's stock fell around 5% year-to-date.
- What Bespoke Extracts Does: Bespoke Extracts Inc is focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products.
- 这笔交易: 定制提取物, Inc. （场外交易代码：BSPK）首席执行官迈克尔·费恩索德 共收购了3,000股股票 平均价格为0.20美元。收购这些股票的成本约为560美元。
- 发生了什么: 该公司的股票今年迄今下跌了约5％。
- 定制提取物的作用: Bespoke Extracts Inc专注于销售其专有的特殊配方、优质、大麻衍生的CBD产品系列。
Check This Out: Top 3 Materials Stocks You May Want To Dump This Month
看看这个： 本月你可能想抛售的三大材料股
Vivos
Vivos
- The Trade: Vivos Inc. (OTC:RDGL) CEO and President Micheal Korenko acquired a total of 100,000 shares at an average price of $0.05. The insider spent 5,360 to buy those shares.
- What's Happening: The company's stock declined 22% over the past month.
- What Vivos Does: Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors.
- 这笔交易: Vivos Inc. (OTC: RDGL) 首席执行官兼总裁迈克尔·科连科 共收购了10万股股票 平均价格为0.05美元。知情人士花了5,360美元购买了这些股票。
- 发生了什么：该公司的股票在过去一个月中下跌了22％。
- Vivos 做什么: Vivos Inc是一家放射肿瘤医疗器械公司。它正在开发RadioGel，这是一种近距离放射治疗设备，由针头注射输送的高度不溶性颗粒组成，使用水聚合物复合材料，用于对不可切除的实体瘤进行高剂量治疗。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
资讯热榜
更新时间